524414 — Norris Medicines Income Statement
0.000.00%
Last trade - 00:00- IN₹164.51m
- IN₹379.92m
- IN₹58.20m
Annual income statement for Norris Medicines, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IAS | IAS | IAS | IAS | IAS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 123 | 94.4 | 83.6 | 56.4 | 58.2 |
| Cost of Revenue | |||||
| Gross Profit | 35.1 | 38.3 | 50 | 29.8 | 23.7 |
| Selling / General / Administrative Expenses | |||||
| Depreciation and Amortization | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 147 | 102 | 80.7 | 63.9 | 66.2 |
| Operating Profit | -24.1 | -7.29 | 2.93 | -7.56 | -8 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -39.9 | -21.8 | -11.9 | -11 | -11.8 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -49.6 | -32.6 | -17.5 | -11.9 | -12.4 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -49.6 | -32.6 | -17.5 | -11.9 | -12.4 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -49.6 | -32.6 | -17.5 | -11.9 | -12.4 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -4.96 | -3.26 | -1.75 | -1.19 | -1.24 |